7.055  0.605 (9.38%)		10-09 15:49
Open: 6.5 High: 7.0842 Volume: 3,103,675		Pre. Close: 6.45 Low: 6.5 Market Cap: 417(M)

Short term
Mid term
Targets	6-month :	8.35	1-year :	9.75
Resists	First :	7.15	Second :	8.35
Pivot price	6.08
Supports	First :	6.24	Second :	5.67
MAs	MA(5) :	6.2	MA(20) :	6.13
	MA(100) :	7.51	MA(250) :	9.54
MACD	MACD :	-0.2	Signal :	-0.4
%K %D	K(14,3) :	63.6	D(3) :	41.3
RSI	RSI(14): 60
52-week	High :	17.97	Low :	5.67

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CGEM ] has closed Bollinger Bands are 20.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	6.65 - 6.68	6.68 - 6.7
Low:	5.79 - 5.82	5.82 - 5.84
Close:	6.4 - 6.45	6.45 - 6.49

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Tue, 23 Sep 2025
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy? - Yahoo Finance

Mon, 22 Sep 2025
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives $26.00 Consensus Price Target from Analysts - MarketBeat

Wed, 17 Sep 2025
HC Wainwright Reiterates Buy Rating for Cullinan Therapeutics (NASDAQ:CGEM) - MarketBeat

Tue, 09 Sep 2025
27.4% Response Rate: Zipalertinib Shows Promise for Hard-to-Treat Lung Cancer with EGFR Mutations - Stock Titan

Tue, 09 Sep 2025
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer - PR Newswire

Thu, 21 Aug 2025
Cullinan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Shares Out	59 (M)
Shares Float	38 (M)
Held by Insiders	0.8 (%)
Held by Institutions	107.6 (%)
Shares Short	6,180 (K)
Shares Short P.Month	5,850 (K)

EPS	-3.17
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	8.32
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-24.5 %
Return on Equity (ttm)	-36.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.97
Qtrly Earnings Growth	0 %
Operating Cash Flow	-172 (M)
Levered Free Cash Flow	-99 (M)

PE Ratio	-2.2
PEG Ratio	0
Price to Book value	0.83
Price to Sales	0
Price to Cash Flow	-2.39

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.